1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field

Italian Firm Needs A Partner For Final Phase III

 
• By Mandy Jackson

Newron’s evenamide worked in a Phase II/III trial as an add-on to antipsychotic drugs in patients with inadequate response to monotherapy at a time when schizophrenia has piqued the interest of big pharma.

Young girl covering her face with her hands after reaching a peak of her depression
Evenamide could be the first add-on to antipsychotics for schizophrenia • Source: Shutterstock

Newron Pharmaceuticals S.p.A.’s evenamide bested placebo as an add-on to antipsychotic drugs in schizophrenia patients with inadequate response to an antipsychotic medication alone in the Phase II/III Study 008A, after the company reported positive long-term Phase II results in treatment-resistant schizophrenia (TRS) at the start of 2024. Plans are under way for a Phase III clinical trial in TRS patients, but the company needs a partner to fund the study, which may now be easier to find.

Key Takeaways

  • Newron’s evenamide succeeded in a Phase II/III clinical trial as an add-on to antipsychotic medicines in schizophrenia patients with inadequate responses to monotherapy.

Schizophrenia and neuropsychiatry have become more popular among big pharma companies recently, with both Bristol Myers Squibb Company and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

More from R&D

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.